OncLive® On Air
by OncLive® On Air
Latest episode
S19 Ep20: ESMO 2026 Data Continue to Shine a Spotlight on…
S19 Ep20: ESMO 2026 Data Continue to Shine a Spotlight on…
About this podcast
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
The newest 50 of 500 episodes
- S19 Ep20: ESMO 2026 Data Continue to Shine a Spotlight on Daraxonrasib’s Activity in Pretreated Metastatic Pancreatic Cancer · 9 min · Season 19 Episode 20Zev A. Wainberg, MD, MSc, discusses subgroup data from RASolute 302 with daraxonrasib in patients with previously treated metastatic pancreatic cancer.
- S19 Ep19: RAS Inhibition With Daraxonrasib Marks a Turning Point in Pancreatic Cancer Management · 24 min · Season 19 Episode 19Drs Park and Marshall traced the evolution of pancreatic cancer management over the past decades, culminating in the emergence of RAS-directed therapy.
- S19 Ep18: Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD · 17 min · Season 19 Episode 18Noa Biran, MD, breaks down key multiple myeloma data shared at the 2026 ASCO Annual Meeting.
- S19 Ep17: Perioperative Research Success Is Set to Transform Bladder Cancer Care After ESMO 2026 · 56 min · Season 19 Episode 17Drs Park and Grivas discuss key bladder cancer data presented at the 2026 ESMO Congress, highlighting the rapidly expanding treatment landscape.
- S19 Ep16: Thorough Treatment Adherence and Selection Anchor Proper TKI Utilization in CML · 9 min · Season 19 Episode 16Fadi Haddad, MD, discusses how to approach proper TKI adherence and selection in clinical practice for CML.
- S19 Ep15: How Allergists Fit Into the Systemic Mastocytosis Management Equation · 16 min · Season 19 Episode 15In today’s episode, we spoke with Nathan A. Boggs, MD, PhD, about the role the allergists play in the diagnosis and management of systemic mastocytosis. Dr Boggs is the director…
- S19 Ep14: Board Review 2026: Top Hematology/Oncology Topics to Know · 20 min · Season 19 Episode 14Drs Armstrong and Tawagi talk through a board exam preparation guide for the days leading up to the hematology and oncology certification exams.
- S19 Ep13: Beyond PD-L1: Refining First-Line Treatment Decisions in Metastatic NSCLC · 21 min · Season 19 Episode 13Drs Juloori and Carbone explore how factors beyond PD-L1 expression, including histology, co-occurring genomic alterations, brain metastases, and patient fitness, can inform…
- S19 Ep12: Order Both IHC and NGS: Defining MET Alterations and Positioning Telisotuzumab Vedotin in Non–Small Cell Lung Cancer · 25 min · Season 19 Episode 12Drs Bazhenova and Patel explain why describing a tumor as “MET positive” is no longer specific enough in non–small cell lung cancer.
- S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape · 22 min · Season 19 Episode 11Drs Sen and Sands discuss lurbinectedin's place in the small cell lung cancer treatment paradigm.
- S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer · 11 min · Season 19 Episode 10Dr Hamilton discusses the FDA approval of tucatinib/trastuzumab/pertuzumab maintenance for unresectable, locally advanced HER2-positive breast cancer.
- S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology · 27 min · Season 19 Episode 9Drs Park and Abraham discuss practice-changing advances in breast cancer, treatment de-escalation, ADCs, and the growing role of AI in oncology.
- S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma · 11 min · Season 19 Episode 8In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed how on-body…
- S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers · 16 min · Season 19 Episode 7Dr Secord discussed the emergence of B7-H4 as an attractive antibody-drug conjugate target in gynecologic cancers.
- S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer · 34 min · Season 19 Episode 6Drs Matulonis and Liu explore the rapidly expanding landscape of novel therapies for ovarian cancer, spanning the next generation of antibody-drug conjugates, resistance…
- S19 Ep5: Navigating Patient-Centric Treatment Administration Strategies in Myeloma · 9 min · Season 19 Episode 5In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed how on-body…
- S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer · 11 min · Season 19 Episode 4Dr Chung discusses the development of atebimetinib in metastatic pancreatic cancer.
- S19 Ep3: FDA Approval Insights: Ropeginterferon Alfa-2b Ushers in Long-Awaited New Treatment Option for Essential Thrombocythemia · 13 min · Season 19 Episode 3In today’s episode, we welcomed Ruben Mesa, MD, FACP, who outlined the significance of the August 2026 FDA approval of ropeginterferon alfa-2b-njft (Besremi) for the treatment of…
- S19 Ep2: FDA Approval Insights: Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma · 12 min · Season 19 Episode 2Dr Reiss Binder discusses the significance of the FDA approval of daraxonrasib for pretreated metastatic pancreatic adenocarcinoma.
- S19 Ep2: Resistance Patterns Shape FGFR Inhibitor Sequencing in Cholangiocarcinoma · 16 min · Season 19 Episode 2Dr Vogel highlights the rationale and growing evidence for sequential FGFR inhibition in FGFR2 fusion–positive cholangiocarcinoma.
- S19 Ep1: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma · 14 min · Season 19 Episode 1In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed evolving…
- S18 Ep50: Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape · 18 min · Season 18 Episode 50Drs Cooper and Choudhury discuss the evolving role of DLL3-targeting T-cell engagers in SCLC, with a focus on tarlatamab-dlle (Imdelltra) and how emerging trial data may reshape…
- S18 Ep49: Start Earlier and Find Your Community: Navigating the Fellowship-to-Faculty Transition Through Mentorship and Specialty-Focused Meetings · 25 min · Season 18 Episode 49Drs Aredo and Bleiberg reflect on the experiences and relationships that shaped their transitions from fellowship into their first faculty positions in thoracic oncology and on…
- S18 Ep48: OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma · 30 min · Season 18 Episode 48Highlights from the PER® CME activity "OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma" — this podcast is not certified for…
- S18 Ep47: Dissecting Diagnostic and Management Factors in Systemic Mastocytosis · 23 min · Season 18 Episode 47In today’s episode, we welcomed Tracy I. George, MD, who provided a pathologist’s perspective on the diagnosis and evolving management considerations for systemic mastocytosis…
- S18 Ep46: Unpacking Data and Upcoming Developments for Olverembatinib in CML · 11 min · Season 18 Episode 46Elias Jabbour, MD, and Dennis Kim, MD, discuss recent data for olverembatininb and its place in CML management.
- S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice · 41 min · Season 18 Episode 45Highlights from the PER® CME activity "Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into…
- S18 Ep44: Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer · 11 min · Season 18 Episode 44Philip A. Philip, MD, discusses TTFields in pancreatic cancer and what phase 3 data has shown in locally advanced disease.
- S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management · 45 min · Season 18 Episode 43Drs Park and Kasi discuss the rise of neoadjuvant immunotherapy in CRC management, framing how this shift fits into the context of larger paradigm changes.
- S18 Ep42: Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer · 12 min · Season 18 Episode 42Nataliya Uboha, MD, PhD, discusses zanidatamab-based regimens, their recent approval, and the HERIZON-GEA-01 trial in gastric cancers.
- S18 Ep41: Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC · 19 min · Season 18 Episode 41Drs Florez and Riess discuss the distinction between HER2 overexpression and HER2 mutations in non–small cell lung cancer.
- S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management · 17 min · Season 18 Episode 40Davide Melisi, MD, PhD, discusses INCB161734 and the DAWN-303 trial evaluating the agent in KRAS G12D–mutated metastatic pancreatic ductal adenocarcinoma.
- S18 Ep39: Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond · 11 min · Season 18 Episode 39Raji Shameem, MD, and Shubham Pant, MD, MBBS, discuss the evolving pancreatic cancer treatment paradigm and novel treatments.
- S18 Ep34: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma—Testing, Treatment, and Supportive Care · 23 min · Season 18 Episode 34Highlights from the PER® CME activity "SimulatED: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma — Testing, Treatment, and Supportive Care" — this…
- S18 Ep38: Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care · 25 min · Season 18 Episode 38Drs Park and Brody highlight the rapidly evolving treatment landscape for B-cell lymphomas, noting advances across frontline and relapsed settings.
- S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE · 14 min · Season 18 Episode 37Drs Armstrong and Tawagi deliver a comprehensive, board-focused review of metastatic NSCLC diagnosis and management for 2026.
- S18 Ep36: Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD · 28 min · Season 18 Episode 36Drs Park and Brody discuss the evolving frontline and relapsed treatment landscape in Hodgkin lymphoma.
- S18 Ep35: The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing · 32 min · Season 18 Episode 35Highlights from the PER® CME activity "The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing" — this podcast is not certified for credit…
- S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC · 29 min · Season 18 Episode 33Highlights from the PER® CME activity "Current Approaches and Future Directions for Early-Stage TNBC" — this podcast is not certified for credit. To participate in the full…
- S18 Ep32: Non–Small Cell Lung Cancer 2026 UPDATE · 14 min · Season 18 Episode 32Two Onc Docs gives a board-focused review of early-stage and locally advanced NSCLC, reflecting recent shifts in staging and perioperative therapy.
- S18 Ep31: FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC · 22 min · Season 18 Episode 31Dr Wong discusses the significance of the FDA’s accelerated approval of vusolimogene oderparepvec-wtpg (Tudriqev; RP1) in combination with nivolumab (Opdivo) for adult patients…
- S18 Ep31: Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD · 28 min · Season 18 Episode 31Eric D. Whitman, MD, and Francis Paul Worden, MD, discuss the integration of immunotherapy into the cutaneous squamous cell carcinoma (CSCC) treatment paradigm and key…
- S18 Ep30: FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO · 8 min · Season 18 Episode 30In today’s episode, we welcomed Sagar Lonial, MD, FACP, FASCO, to discuss the significance of the August 2026 FDA accelerated approval of iberdomide (Zenbexus) plus daratumumab…
- S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment · 29 min · Season 18 Episode 29Highlights from the PER® CME activity "MET Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment" — this podcast is not certified…
- S18 Ep28: Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD · 17 min · Season 18 Episode 28Dr Valerin discusses the role of liposomal irinotecan in pancreatic cancer management and factors influencing the decision to use this agent in practice.
- S18 Ep27: Key Considerations for Health Equity and Patient-Centered Care in TNBC · 26 min · Season 18 Episode 27Highlights from the PER® CME activity "Key Considerations for Health Equity and Patient-Centered Care in TNBC" — this podcast is not certified for credit. To participate in the…
- S18 Ep26: FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD · 11 min · Season 18 Episode 26Dr Brufsky discusses the FDA approval of gedatolisib plus fulvestrant ± palbociclib for hormone receptor–positive, PIK3CA wild-type advanced breast cancer.
- S18 Ep25: Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD · 16 min · Season 18 Episode 25Jonathan Trent, MD, PhD, discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.
- S18 Ep24: Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD · 23 min · Season 18 Episode 24Drs Park and Liu discuss precision oncology, bispecific antibodies, and next-generation targeted therapies in NSCLC.
- S18 Ep23: From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC · 26 min · Season 18 Episode 23Highlights from the PER® CME activity "From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC" — this podcast is not certified for credit. To participate in…
